CompletedPhase 2

The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.

Mexico80 participantsStarted 2017-07-01

Plain-language summary

In double-blind clinical trial, determine renal recovery with two different furosemide strategies in patients with type 1 cardiorenal syndrome.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Comply with both clinical diagnosis of acute kidney injury by serum creatinine according to the Kidney Disease Improving Global Outcomes (KDIGO) 2012 guidelines and acute decompensate heart failure as clinical assessed by the clinical team in charge. * Have agreed and signed informed consent Exclusion Criteria: * Patient in chronic dialysis either peritoneal dialysis or hemodialysis. * History of being a renal transplant recipient * History of acute kidney injury according to the KDIGO 2012 guidelines and / or renal replacement therapy in the last 3 months * Pregnancy * Impossibility to administer medication by the oral route

What they're measuring

Number of Participants With Renal Function Recovery Defined as a Return to Individual Baseline Serum Creatinine Values

Timeframe: Up to 96 hours after intervention started

Trial details

NCT IDNCT04393493

SponsorHospital Civil de Guadalajara

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-04-01

Results submitted2020-07-27

View on ClinicalTrials.gov More Cardiorenal Syndrome trials